drugset / Trial / NCT05933187
A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this trial is to evaluate plasma concentrations of emraclidine following single dose oral administration of different emraclidine immediate release (IR) tablets in healthy participants.
Timeline
- Start
- 2023-07-19
- Primary completion
- 2023-09-12
- Completion
- 2023-09-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emraclidine | Small molecule | 30 mg | Oral |
Indications
No indication recorded.